Pascal Lebray
Overview
Explore the profile of Pascal Lebray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alric L, Brusq C, Migueres M, Faure S, Lebray P, Viallard J, et al.
Lupus Sci Med
. 2025 Mar;
12(1).
PMID: 40044500
Objectives: Some patients with SLE or Gougerot-Sjögren's disease (GSD) receive long-term treatment with hydroxychloroquine (HCQ), sometimes combined with immunosuppressive therapy (IS). This study sought to assess whether long-term HCQ therapy...
2.
Tellez L, Rincon D, Payance A, Jaillais A, Lebray P, Rodriguez de Santiago E, et al.
J Hepatol
. 2024 Sep;
82(3):480-489.
PMID: 39260705
Background & Aims: Fontan-type surgery is a palliative procedure for congenital heart disease with univentricular physiology that may, in the long term, lead to advanced chronic liver disease. Herein, we...
3.
Scheifer C, Lebrun-Vignes B, Lebray P, Tubach F, Dechartres A
Clin Res Hepatol Gastroenterol
. 2024 Apr;
48(6):102356.
PMID: 38685563
Background And Aims: A recent single-center study reported a significant increase in acute myeloid leukaemia (AML) cases, including mixed-phenotype acute leukaemia (MPAL), after exposure to direct acting agents (DAA). We...
4.
Allaire M, Roux C, Akhavan S, Lebray P, Thabut D
Clin Res Hepatol Gastroenterol
. 2023 Sep;
47(9):102213.
PMID: 37774918
No abstract available.
5.
Poynard T, Deckmyn O, Peta V, Sakka M, Lebray P, Moussalli J, et al.
Hepatol Commun
. 2023 Sep;
7(10).
PMID: 37738404
Background And Aims: Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28 homozygosity in Europeans and is phenotypically defined by hyperbilirubinemia using total bilirubin (TB) cutoff ≥1mg/dL (17 μmol/L). The prevalence...
6.
Cortesi P, Vigano R, Conti S, Lenci I, Volpes R, Martini S, et al.
Transpl Int
. 2023 Feb;
36:10954.
PMID: 36793896
The European Liver and Intestine Transplant Association, ELITA, promoted a Consensus Conference involving 20 experts across the world which generated updated guidelines on HBV prophylaxis in liver transplant candidates and...
7.
Meunier L, Belkacemi M, Pageaux G, Radenne S, Vallet-Pichard A, Houssel-Debry P, et al.
Viruses
. 2023 Jan;
15(1).
PMID: 36680177
Background: Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the...
8.
Thabut D, Bouzbib C, Meunier L, Haas M, Weiss N, Louvet A, et al.
Liver Int
. 2023 Jan;
43(4):750-762.
PMID: 36625084
Hepatic encephalopathy (HE) is a frequent and severe complication of liver disease with poor patient outcomes. However, it is a poorly understood complication, with no consensus for diagnosis. Therefore, HE...
9.
Coilly A, Sebagh M, Fougerou-Leurent C, Pageaux G, Leroy V, Radenne S, et al.
Clin Res Hepatol Gastroenterol
. 2022 Sep;
46(9):102024.
PMID: 36122871
Introduction: Hepatitis C virus (HCV) may recur after liver transplantation (LT) in the severe form of fibrosing cholestatic hepatitis (FCH). The prognosis dramatically improved by the use of direct acting...
10.
Scheifer C, Luckina E, Lebrun-Vignes B, Diop A, Damais-Thabut D, Roos-Weil D, et al.
Clin Res Hepatol Gastroenterol
. 2022 Aug;
46(8):102000.
PMID: 35933093
Background: After several cases of peculiar hematological malignancies following introduction of new oral anti-hepatitis C virus (HCV) treatments in our recent practice, we aimed to systematically identify all cases of...